Idorsia Ltd Total Liabilities

Latest as of March 2026: CHF1.66 Billion CHF ≈ $2.09 Billion USD

Idorsia Ltd total liabilities. Based on the latest financial reports, Idorsia Ltd (IDIA) has total liabilities worth CHF1.66 Billion CHF (≈ $2.09 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Idorsia Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Idorsia Ltd (2016–2025)

Total liabilities of Idorsia Ltd from 2016 to 2025. This chart illustrates how Idorsia Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore IDIA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Idorsia Ltd Competitors by Total Liabilities

The table below lists competitors of Idorsia Ltd ranked by their total liabilities.

Company Country Total Liabilities
Guanglian Aviation Industry Co Ltd
SHE:300900
China CN¥3.01 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥823.87 Million
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
Mexico MX$21.44 Billion
Plejd AB (publ)
F:3CA
Germany €346.32 Million
Coretronic
TWO:5371
Taiwan NT$27.69 Billion
Baltic Classifieds Group PLC
LSE:BCG
UK €95.38 Million
Arcelik AS
IS:ARCLK
Turkey TL513.70 Billion
Focus Lightings Tech Co Ltd
SHE:300708
China CN¥2.53 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Idorsia Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Idorsia Ltd total assets.

Liquidity & Leverage Metrics

Idorsia Ltd Total Liabilities Ratios Explained

Idorsia Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.60 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.45 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Idorsia Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Idorsia Ltd (2016–2025)

The table below shows the annual total liabilities of Idorsia Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 CHF1.60 Billion
≈ $2.03 Billion
-6.69%
2024-12-31 CHF1.72 Billion
≈ $2.17 Billion
+16.98%
2023-12-31 CHF1.47 Billion
≈ $1.86 Billion
-6.16%
2022-12-31 CHF1.57 Billion
≈ $1.98 Billion
+13.52%
2021-12-31 CHF1.38 Billion
≈ $1.74 Billion
+62.23%
2020-12-31 CHF849.88 Million
≈ $1.07 Billion
+1.19%
2019-12-31 CHF839.85 Million
≈ $1.06 Billion
+12.11%
2018-12-31 CHF749.14 Million
≈ $947.12 Million
+35.62%
2017-12-31 CHF552.37 Million
≈ $698.34 Million
+35.67%
2016-12-31 CHF407.15 Million
≈ $514.75 Million
--

About Idorsia Ltd

SW:IDIA Switzerland Biotechnology
Market Cap
$1.44 Billion
CHF1.14 Billion CHF
Market Cap Rank
#8427 Global
#121 in Switzerland
Share Price
CHF4.47
Change (1 day)
-2.44%
52-Week Range
CHF2.93 - CHF6.89
All Time High
CHF33.62
About

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more